ltd4 การใช้

• The eoxins are 14, 15-analogs of LTA4, LTC4, LTD4, and LTE4.
• The CysLTR1 300S variant exhibited significant increased sensitivity to LTD4 and LTC4 suggesting that this hypersensitivity underlies its association with atopy.
• It is formed from the sequential conversion of LTC4 to LTD4 and then to LTE4, which is the final and most stable cysteinyl leukotriene.
• The Glu and Gly residues of LTC4 may be removed step-wise by gamma-glutamyltransferase and a dipeptidase to form sequentially LTD4 and LTE4.
• Montelukast, Zafirlukast, and Pranlukast are receptor antagonists for the Cysteinyl leukotriene receptor 1 which contributes to mediating the actions of LTC4, LTD4, and LTE4.
• The GPR17 receptor, also termed the uracil nucleotide / cysteinyl leukotriene receptor, was initially defined as a receptor for LTC4, LTD4, and uracil nucleotides.
• By comparison, the stimulating potencies of these CysLTs for CysLTR1 is LTD4 > LTC4 > LTE4 with LTD4 showing 10-fold greater potency on CysLTR1 than CysLTR2.
• By comparison, the stimulating potencies of these CysLTs for CysLTR1 is LTD4 > LTC4 > LTE4 with LTD4 showing 10-fold greater potency on CysLTR1 than CysLTR2.
• CYSLTR2, by binding these cysteinyl LTs ( CysLTs; viz, LTC4, LTD4, and to a much lesser extent, LTE4 ) contributes to mediating various allergic and hypersensitivity reactions in humans.
• Compared to the short half lives of LTC4 and LTD4, LTE4 is relatively stable and accumulates in breath condensation, in plasma, and in urine, making it the dominant cysteinyl leukotriene detected in biologic fluids.
• In striking contrast to these studies, studies concentration on neural tissues continue to find that Oligodendrocyte progenitor cells express GPR17 and respond through this receptor to LTC4, LTD4, and certain purines ( see GPR17 # Function ).
• Finally, and in striking contrast to these studies, repeated studies on neural tissues find that Oligodendrocyte progenitor cells express GPR17 and respond through this receptor to LTC4, LTD4, and certain purines ( see GPR17 # Function ).
• Perhaps related to this difference in CysLT sensitivities, cells co-expressing CysLTR2 and CysLTR1 may may exhibit lower sensitivity to LTD4 than do cells expressing only CysLTR1; in consequence, CysLTR2 has been suggested to dampen CysLTR1's activities.
• Furthermore, blockers of LTC4, LTD4, and LTE4 synthesis ( i . e . ALOX5 inhibitors ) as well as of LTC4 and LTD4 receptor antagonists have proven inferior to corticosteroids as single drug therapy for persistent asthma, particularly in patients with airway obstruction.
• Furthermore, blockers of LTC4, LTD4, and LTE4 synthesis ( i . e . ALOX5 inhibitors ) as well as of LTC4 and LTD4 receptor antagonists have proven inferior to corticosteroids as single drug therapy for persistent asthma, particularly in patients with airway obstruction.
• Other studies on model cells for allergy have defined GPR17 ( also termed the uracil nucleotide / cysteinyl leukotriene receptor ) as a receptor not only uracil nucleotides but also for CysLTs, with CysLTs having the following potencies LTD4 > LTC4 > LTE4 in stimulating GPR17-bearing cells.
• Rather, they find that : "'a ) "'cells expressing both CysLTR1 and GPR17 receptors exhibit a marked reduction in binding and responding to LTD4 and "'b ) "'mice lacking GPR17 are hyper-responsive to igE in a model for passive cutaneous anaphylaxis.
• Acting through these G proteins and their subunits, ligand-bound CysLTR1 activates a series of pathways that lead to cell function ( see Gq alpha subunit # function and Ga subunit # function for details ); the order of potency of the cysLTs in stimulating CysLTR2 is LTD4 = LTC4 > LTE4 with LTE4 probably lacking sufficient potency to have much activity that operates through CysLTR1 in vivo.
• In addition to CysLTR1, GPR99 ( also termed the oxoglutarate receptor or, sometimes, CysLTR3 ) appears to be an important receptor for CysLTs, particularly for LTE4 : the CystLTs show relative potencies of LTE4 > LTC4 > LTD4 in stimulating GPR99-bearing cells and GPR99-deficient mice exhibit a dose-dependent loss of vascular permeability responses in skin to LTE4 but not to LTC4 or LTD4.
• In addition to CysLTR1, GPR99 ( also termed the oxoglutarate receptor or, sometimes, CysLTR3 ) appears to be an important receptor for CysLTs, particularly for LTE4 : the CystLTs show relative potencies of LTE4 > LTC4 > LTD4 in stimulating GPR99-bearing cells and GPR99-deficient mice exhibit a dose-dependent loss of vascular permeability responses in skin to LTE4 but not to LTC4 or LTD4.